Lymphoid Interstitial Pneumonia in Common Variable Immune Deficiency - Case Report With Disease Monitoring in Various Therapeutic Options: Pleiotropic Effects of Rituximab Regimens
Przemyslaw Zdziarski, Andrzej Gamian, Przemyslaw Zdziarski, Andrzej Gamian
Abstract
Lymphoid interstitial pneumonia (LIP) is a rare lymphoproliferative disease. LIP in common variable immunodeficiency (CVID) was observed in a patient during immunomodulatory therapy after progression of the disease (i.e., glucocorticoids, immunoglobulin dose escalation, and finally rituximab). Due to humoral immunodeficiency and serious serum sickness rituximab was used initially at a low dose (150 mg/m2 weekly). It resulted in temporary remission with the decrease of serum paraproteinemia, β2-microglobulin (β2M) and SUV decrease as well as increase of FVC. Owing to the relapse after 6-month remission in the second cycle a standard dose of rituximab was used (375 mg/m2). Therapeutic regimen with 375 mg/m2 of Rtx in optimal schedule (i.e., every 3 weeks) resulted in no longer remission but higher incidence of opportunistic infections. Finally, after another cycle of immunotherapy FVC, paraproteinemia and β2M level normalization were observed as well as the decrease of severe splenomegaly. In laboratory and immunological progress the increase of NK and NKT cells was observed after the initial dose but the standard one caused NK cell increase only. Unfortunately, the decrease of CD19+Bcells was comparable between both doses, as was the decline of FoxP3+ regulatory T cell. On the contrary, after the low dose absolute T cell (both CD4 and CD8) number decreased but after the standard one - it normalized. Rtx (especially in low dose) brought further increase of persistent T cell activation (CD38+ T cells made up 79%). Innate immune response and the decrease of Treg are a compensatory pathways for the decrease of B and T cells. Immunodeficiency requires a different investigative approach to a immunotherapy. Clinical Trial Registration: ClinicalTrials.gov, NCT02789397.
Keywords: FoxP3+ regulatory T cells (Treg); common variable immune deficiency (CVID); immune dysregulation; lymphoid interstitial pneumonia (LIP); lymphoproliferative disease (LPD); natural killer (NK) natural killer T-cells (NKT); rituximab, innate immune response.
Figures
References
- Arish N., Eldor R., Fellig Y., Bogot N., Laxer U., Izhar U., et al. (2007). Lymphocytic interstitial pneumonia associated with common variable immunodeficiency resolved with intravenous immunoglobulins. Thorax 61 1096–1097. 10.1136/thx.2004.029819
- Besada E., Nossent J. C. (2016) CD4 cell count, and CD4/CD8 ratio increase during rituximab maintenance in granulomatosis with polyangiitis patients. PeerJ 4:e2487. 10.7717/peerj.2487
- Burton C., Kaczmarski R., Jan-Mohamed R. (2003). Interstitial Pneumonitis related to Rituximab therapy. N. Engl. J. Med. 348 2690–2691. 10.1056/NEJM200306263482619
- Chapel H., Lucas M., Lee M., Bjorkander J., Webster D., Grimbacher B., et al. (2008). Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 112 277–286. 10.1182/blood-2007-11-124545
- Chase N. M., Verbsky J. W., Hintermeyer M. K., Waukau J. K., Tomita-Mitchell A., Casper J. T., et al. (2013). Use of combination chemotherapy for treatment of granulomatous and lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiency (CVID). J. Clin. Immunol. 33 30–39. 10.1007/s10875-012-9755-9753
- Deng Q. I., Bai X., Lv H. R., Xiao X., Zhao M. F., Li Y. M., et al. (2015). Anti-CD20 antibody induces the improvement of cytokine-induced killer cell activity via the STAT and MAPK/ERK signaling pathways. Exp. Ther. Med. 9 1215–1222. 10.3892/etm.2015.2264
- Finger E., Scheinberg M. (2007). Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia. J. Clin. Rheumatol. 13 94–95. 10.1097/01.rhu.0000262585.18582.1e
- Garnelo M., Tan A., Her Z., Yeong J., Lim C. J., Chen J., et al. (2017). Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. Gut 66 342–351. 10.1136/gutjnl-2015-310814
- Golay J., Semenzato G., Rambaldi A., Foà R., Gaidano G., Gamba E., et al. (2013). Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. mAbs 5 826–837. 10.4161/mabs.26008
- Hurst J. R., Verma N., Lowe D., Baxendale H. E., Jolles S., Kelleher P., et al. (2017). British Lung Foundation/United Kingdom Primary Immunodeficiency Network Consensus Statement on the Definition, Diagnosis, and Management of Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders. J. Allergy Clin. Immunol. Pract. 5 938–945. 10.1016/j.jaip.2017.01.021
- Jolles S., Carne E., Brouns M., El-Shanawany T., Williams P., Marshall C., et al. (2017). FDG PET-CT imaging of therapeutic response in granulomatous lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID). Clin. Exp. Immunol. 187 138–145. 10.1111/cei.12856
- Katchar K., Söderström K., Wahlstrom J., Eklund A., Grunewald J., Grunewald al. (2005). Characterisation of natural killer cells and CD56+ T-cells in sarcoidosis patients. Eur. Respir. J. 26 77–85. 10.1183/09031936.05.00030805
- Korosec P., Osolnik K., Kern I., Silar M., Mohorcic K., Kosnik M., et al. (2007). Expansion of pulmonary CD8CD56 natural killer T-cells in hypersensitivity Pneumonitis. Chest 132 1291–129. 10.1378/chest.07-0128
- Lioté H., Cadranel J., Lioté F. (2010). Rituximab-induced pneumonitis: steroid therapy or not? Pediatr. Pulmonol. 45 412–413.
- Miller M. R., Hankinson J., Brusasco V., Burgos F., Casaburi R., Coates A., et al. (2005). Standardisation of spirometry. Eur. Respir. J. 26 319–338. 10.1183/09031936.05.00034805
- Paquin-Proulx D., Santos B. A., Carvalho K. I., Toledo-Barros M., Barreto de Oliveira A. K., Kokron C. M., et al. (2013). IVIg immune reconstitution treatment alleviates the state of persistent immune activation and suppressed CD4 T cell counts in CVID. PLoS One 8:e75199. 10.1371/journal.pone.0075199
- Ren Z., Guo J., Liao J., Luan Y., Liu Z., Sun Z., et al. (2017). CTLA-4 limits anti-CD20-mediated tumor regression. Clin. Cancer Res. 23 193–203. 10.1158/1078-0432.CCR-16-0040
- Rizzi M., Neumann C., Fielding A. K., Marks R., Goldacker S., Thaventhiran J., et al. (2011). Outcome of allogeneic stem cell transplantation in adults with common variable immunodeficiency. J. Allergy Clin. Immunol. 128 1371.e2–1374.e2. 10.1016/j.jaci.2011.07.055
- Shimizu Y., Dobashi K., Endou K., Ono A., Yanagitani N., Utsugi M., et al. (2010). Decreased interstitial Foxp3+lymphocytes in usual interstitial pneumonia with discrepancy of CXCL12/CXCR4 axis. Int. J. Immunopathol. Pharmacol. 23 449–461. 10.1177/039463201002300207
- Swartz M. A., Vivino F. B. (2011). Dramatic reversal of lymphocytic interstitial pneumonitis in Sjögren’s syndrome with rituximab. J. Clin. Rheumatol. 17:454. 10.1097/RHU.0b013e31823ac199
- Tansy J., McLean-Tooke A. (2013). Rituximab effective for lymphocytic interstitial pneumonitis associated with sjogren’s syndrome: a case report: cgr013. Int. Med. J. 43:25.
- Trujillo C. M., Muskus C., Arango J., Patiño P. J., Montoya C. J. (2011). Quantitative and functional evaluation of innate immune responses in patients with common variable immunodeficiency. J. Invest. Allergol. Clin. Immunol. 21 207–215.
- Vitale J., Convers K. D., Goretzke S., Guzman M., Noyes B., Parkar N., et al. (2015). Serum IL-12 and soluble IL-2 receptor levels as possible biomarkers of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency: a case report. J. Allergy Clin. Immunol. Pract. 3 273–276. 10.1016/j.jaip.2014.09.019
- Wehr C., Gennery A. R., Lindemans C., Schulz A., Hoenig M., Marks R., et al. (2015). Multicenter experience in hematopoietic stem cell transplantation in 25 patients with common variable immunodeficiency. J. Allergy Clin. Immunol. 135 988.e6–997.e6. 10.1016/j.jaci.2014.11.029
- Zaja F., Volpetti S., Chiozzotto M., Puglisi S., Isola M., Buttignol S., et al. (2012), Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia. Am. J. Hematol. 87 886–889. 10.1002/ajh.23272
- Zdziarski P., Dworacki G., Korzeniowska-Kowal A., Ziemnicka K. (2016). Role of chemokine signalling in the pathogenesis of good’s syndrome-case reports, clinical characterization from single-centre perspective. Immunome Res. 12:2 10.4172/1745-7580.10000119
- Zdziarski P., Gamian A., Dworacki G. (2017). A case report of lymphoid intestitial pneumonia in common variable immunodeficiency: oligoclonal expansion of effector lymphocytes with preferential cytomegalovirus-specific immune response and lymphoproliferative disease promotion. Medicine 96:e7031. 10.1097/MD.0000000000007031
Source: PubMed